BR9809484A - Formulação farmacêutica oral revestida entérica, processo para a manufatura da mesma, uso de uma qualidade de hidroxipropil metilcelulose (hpmc) de baixa viscosidade, e, processo para o tratamento de doenças gastrointestinais em mamìferos, incluindo o homem. - Google Patents

Formulação farmacêutica oral revestida entérica, processo para a manufatura da mesma, uso de uma qualidade de hidroxipropil metilcelulose (hpmc) de baixa viscosidade, e, processo para o tratamento de doenças gastrointestinais em mamìferos, incluindo o homem.

Info

Publication number
BR9809484A
BR9809484A BR9809484-0A BR9809484A BR9809484A BR 9809484 A BR9809484 A BR 9809484A BR 9809484 A BR9809484 A BR 9809484A BR 9809484 A BR9809484 A BR 9809484A
Authority
BR
Brazil
Prior art keywords
hpmc
low viscosity
hydroxypropyl methylcellulose
pharmaceutical formulation
omeprazole
Prior art date
Application number
BR9809484-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Magnus Erickson
Lars Josefsson
Original Assignee
Astra Aktibolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20407122&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9809484(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Aktibolag filed Critical Astra Aktibolag
Publication of BR9809484A publication Critical patent/BR9809484A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BR9809484-0A 1997-05-28 1998-05-18 Formulação farmacêutica oral revestida entérica, processo para a manufatura da mesma, uso de uma qualidade de hidroxipropil metilcelulose (hpmc) de baixa viscosidade, e, processo para o tratamento de doenças gastrointestinais em mamìferos, incluindo o homem. BR9809484A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9702000A SE9702000D0 (sv) 1997-05-28 1997-05-28 New pharmaceutical formulation
PCT/SE1998/000922 WO1998053803A1 (en) 1997-05-28 1998-05-18 Pharmaceutical formulation of omeprazole

Publications (1)

Publication Number Publication Date
BR9809484A true BR9809484A (pt) 2000-06-20

Family

ID=20407122

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9809484-0A BR9809484A (pt) 1997-05-28 1998-05-18 Formulação farmacêutica oral revestida entérica, processo para a manufatura da mesma, uso de uma qualidade de hidroxipropil metilcelulose (hpmc) de baixa viscosidade, e, processo para o tratamento de doenças gastrointestinais em mamìferos, incluindo o homem.

Country Status (40)

Country Link
US (1) US6090827A (https=)
EP (1) EP0984773B1 (https=)
JP (1) JP4649001B2 (https=)
KR (1) KR100540721B1 (https=)
CN (1) CN1123338C (https=)
AR (1) AR012698A1 (https=)
AT (1) ATE234078T1 (https=)
AU (1) AU722879B2 (https=)
BR (1) BR9809484A (https=)
CA (1) CA2290531C (https=)
CZ (1) CZ298972B6 (https=)
DE (1) DE69812089T2 (https=)
DK (1) DK0984773T3 (https=)
DZ (1) DZ2494A1 (https=)
EE (1) EE03903B1 (https=)
EG (1) EG24044A (https=)
ES (1) ES2195342T3 (https=)
HR (1) HRP980260B1 (https=)
HU (1) HU229154B1 (https=)
ID (1) ID24654A (https=)
IL (1) IL132895A0 (https=)
IS (1) IS2856B (https=)
MA (1) MA26497A1 (https=)
MY (1) MY122298A (https=)
NO (1) NO328100B1 (https=)
NZ (1) NZ500886A (https=)
PL (1) PL194634B1 (https=)
PT (1) PT984773E (https=)
RS (1) RS49629B (https=)
RU (1) RU2207121C2 (https=)
SA (1) SA98190304B1 (https=)
SE (1) SE9702000D0 (https=)
SI (1) SI0984773T1 (https=)
SK (1) SK286625B6 (https=)
TN (1) TNSN98068A1 (https=)
TR (1) TR199902890T2 (https=)
TW (1) TW575435B (https=)
UA (1) UA71541C2 (https=)
WO (1) WO1998053803A1 (https=)
ZA (1) ZA984178B (https=)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6174548B1 (en) * 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
CA2298823C (en) * 1998-04-20 2011-06-07 Eisai Co., Ltd. Stabilized composition comprising a benzimidazole type compound
SE9803772D0 (sv) * 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
SE9902386D0 (sv) * 1999-06-22 1999-06-22 Astra Ab New formulation
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
ES2168043B1 (es) 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
MXPA02003762A (es) 1999-10-20 2002-09-30 Eisai Co Ltd Metodos para estabilizar compuestos basados en benzimidazol.
US20040092511A1 (en) * 1999-12-10 2004-05-13 Billstein Stephan Anthony Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders
US20020192299A1 (en) * 2000-12-28 2002-12-19 Rajneesh Taneja Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
JP2002234842A (ja) * 2001-02-09 2002-08-23 Kyowa Yakuhin Kogyo Kk 内服腸溶性製剤
US20040006111A1 (en) * 2002-01-25 2004-01-08 Kenneth Widder Transmucosal delivery of proton pump inhibitors
US20040082618A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of acid labile drugs
FR2843121B3 (fr) 2002-08-02 2004-09-10 Rhodia Chimie Sa Agent ignifugeant, procede de preparation et l'utilisation de cet agent
US20070243251A1 (en) * 2002-12-20 2007-10-18 Rajneesh Taneja Dosage Forms Containing A PPI, NSAID, and Buffer
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US20040146558A1 (en) * 2003-01-28 2004-07-29 Kyowa Pharmaceutical Co., Ltd. Oral enteric-coated preparation
JP4567340B2 (ja) * 2003-01-29 2010-10-20 武田薬品工業株式会社 被覆製剤の製造方法
ZA200506397B (en) * 2003-01-29 2006-11-29 Takeda Pharmaceutical Process for producing coated preparation
RU2359671C2 (ru) * 2003-01-29 2009-06-27 Такеда Фармасьютикал Компани Лимитед Способ получения препарата с покрытием
MXPA05007883A (es) 2003-01-29 2005-09-21 Takeda Pharmaceutical Proceso para producir una preparacion recubierta.
US20040248942A1 (en) * 2003-02-20 2004-12-09 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
US20050042277A1 (en) * 2003-07-17 2005-02-24 Irukulla Srinivas Pharmaceutical compositions having a swellable coating
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
CN1311824C (zh) * 2004-04-21 2007-04-25 常州市第四制药厂有限公司 奥美拉唑肠溶微粒制剂及制备方法
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
ES2324354T3 (es) * 2005-07-29 2009-08-05 Rottapharm S.P.A. Combinacion terapeutica de itriglumida e inhibidores de la bomba de protones en el tratamiento de trastornos gastrointestinales y relacionados.
AU2007266574A1 (en) * 2006-06-01 2007-12-06 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
KR101436516B1 (ko) * 2007-07-23 2014-09-02 주식회사태평양제약 코팅된 펠렛을 함유하는 현탁정 및 이의 제조방법
CN103126998A (zh) * 2007-09-28 2013-06-05 西梯茜生命工学股份有限公司 一种固态分散体和含有埃索美拉唑的药物组合物
RU2477123C2 (ru) * 2008-03-28 2013-03-10 Феррер Интернасионал, С.А. Капсула и лекарственное средство для профилактики сердечно-сосудистых заболеваний
HRP20140640T1 (hr) 2008-08-19 2014-11-21 Xenoport, Inc. Prolijekovi monometil estera fumarne kiseline, farmaceutski sastavi iz toga i postupci njihove uporabe
US10945984B2 (en) 2012-08-22 2021-03-16 Arbor Pharmaceuticals, Llc Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
AU2013305684B2 (en) 2012-08-22 2016-11-24 Xenoport, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
CN102961356A (zh) * 2012-12-11 2013-03-13 山西云鹏制药有限公司 一种含奥美拉唑的蓝色肠溶片剂的制备方法
WO2014160633A1 (en) 2013-03-24 2014-10-02 Xenoport, Inc. Pharmaceutical compositions of dimethyl fumarate
EP3041467A1 (en) 2013-09-06 2016-07-13 XenoPort, Inc. Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use
US20150079180A1 (en) * 2013-09-18 2015-03-19 Xenoport, Inc. Nanoparticle compositions of dimethyl fumarate
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
WO2016174664A1 (en) 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US20230058473A1 (en) 2020-01-27 2023-02-23 Towa Pharmaceutical Co., Ltd. Esomeprazole oral preparation and method for producing the same
KR102432084B1 (ko) 2021-11-16 2022-08-12 알리코제약(주) S-오메프라졸을 함유하는 안정성이 개선되고 소형화된 정제
JP2025532389A (ja) 2022-10-04 2025-09-29 ザビリュク,アルセニー 大動脈弁の石灰化の抑制

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
JPH05255088A (ja) * 1991-11-05 1993-10-05 Yoshitomi Pharmaceut Ind Ltd 抗潰瘍剤含有製剤
JP2669446B2 (ja) * 1992-03-23 1997-10-27 信越化学工業株式会社 医薬品コーティング液用原料粉粒体
FR2692146B1 (fr) * 1992-06-16 1995-06-02 Ethypharm Sa Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention.
JPH0733659A (ja) * 1992-07-17 1995-02-03 Yoshitomi Pharmaceut Ind Ltd 抗潰瘍剤含有製剤
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
EE03305B1 (et) * 1994-07-08 2000-12-15 Astra Aktiebolag Paljuosaline tableteeritud annusvorm I
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms

Also Published As

Publication number Publication date
ES2195342T3 (es) 2003-12-01
TW575435B (en) 2004-02-11
HK1025744A1 (en) 2000-11-24
PL194634B1 (pl) 2007-06-29
SI0984773T1 (en) 2003-10-31
TR199902890T2 (xx) 2000-02-21
SA98190304B1 (ar) 2006-10-11
DK0984773T3 (da) 2003-07-07
HRP980260A2 (en) 1999-02-28
EE9900540A (et) 2000-06-15
CZ298972B6 (cs) 2008-03-26
DZ2494A1 (fr) 2003-01-25
WO1998053803A1 (en) 1998-12-03
KR100540721B1 (ko) 2006-01-10
EP0984773B1 (en) 2003-03-12
CZ420299A3 (cs) 2000-05-17
IS2856B (is) 2013-11-15
SK159099A3 (en) 2000-06-12
PL337237A1 (en) 2000-08-14
ZA984178B (en) 1998-11-30
YU60899A (sh) 2002-06-19
IS5245A (is) 1999-11-11
ATE234078T1 (de) 2003-03-15
TNSN98068A1 (fr) 2005-03-15
IL132895A0 (en) 2001-03-19
CA2290531A1 (en) 1998-12-03
HRP980260B1 (en) 2003-10-31
HU229154B1 (en) 2013-09-30
RU2207121C2 (ru) 2003-06-27
NO995809D0 (no) 1999-11-26
US6090827A (en) 2000-07-18
SK286625B6 (sk) 2009-02-05
UA71541C2 (uk) 2004-12-15
PT984773E (pt) 2003-07-31
CA2290531C (en) 2006-12-12
EP0984773A1 (en) 2000-03-15
SE9702000D0 (sv) 1997-05-28
JP4649001B2 (ja) 2011-03-09
RS49629B (sr) 2007-08-03
JP2002500665A (ja) 2002-01-08
MA26497A1 (fr) 2004-12-20
HUP0002182A2 (hu) 2002-05-29
AU7680398A (en) 1998-12-30
CN1123338C (zh) 2003-10-08
HUP0002182A3 (en) 2003-02-28
NZ500886A (en) 2001-11-30
MY122298A (en) 2006-04-29
CN1258217A (zh) 2000-06-28
NO995809L (no) 2000-01-28
ID24654A (id) 2000-07-27
EG24044A (en) 2008-04-13
KR20010013104A (ko) 2001-02-26
NO328100B1 (no) 2009-12-07
AR012698A1 (es) 2000-11-08
DE69812089D1 (de) 2003-04-17
AU722879B2 (en) 2000-08-10
EE03903B1 (et) 2002-12-16
DE69812089T2 (de) 2004-03-04

Similar Documents

Publication Publication Date Title
BR9809484A (pt) Formulação farmacêutica oral revestida entérica, processo para a manufatura da mesma, uso de uma qualidade de hidroxipropil metilcelulose (hpmc) de baixa viscosidade, e, processo para o tratamento de doenças gastrointestinais em mamìferos, incluindo o homem.
BR9915087A (pt) Formulação farmacêutica oral revestida entérica, uso de uma qualidade de hidroxipropil celulose (hpc), processo para a munufatura de uma formulação farmacêutica oral revestida entérica, uso de uma formulação farmacêutica, e, método para o tratamento de doenças gastrointestinais em mamìferos, incluindo o homem
PT1308159E (pt) Composicao farmaceutica contendo um omeprazole labil a acidos e processo para a sua preparacao
DK122291A (da) Benzimidazolderivat og fysiologisk acceptable salte heraf samt fremgangsmaade til fremstilling af samme
CL2009000805A1 (es) Composicion farmaceutica que comprende a una sal sodica del enantiomero (-) de 5-metoxi-2[[(4-metoxi-3,5-dimetil-2-piridinil)metil]sulfinil]-1h-bencimidazol ((-)-omeprazol); y su uso en la inhibicion de la secrecion de acido gastrico y para tratar enfermedades inflamatorias gastrointestinales. (divisional solicitud 3570-00).
RU99126869A (ru) Фармацевтический препарат омепразола
BR0011894A (pt) Forma de dosagem oral, processo para a fabricação de forma de dosagem, uso de forma de dosagem farmacêutica oral, e, métodos para aumentar inibição de secreção do ácido gástrico e para aumentar o efeito terapêutico no tratamento de distúrbios gastrointestinais associados com excesso de secreção ácida
DE69906518D1 (de) Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
YU36700A (sh) Oralni farmaceutski oblik za doziranje sa produženim oslobađanjem
HUP0100347A2 (hu) Gyomorvédett omeprazol mikrogranulátumok, eljárás előállításukra és ezeket tartalmazó gyógyászati készítmények
ATE110379T1 (de) Therapeutisch aktive substituierte benzimidazole und verfahren zu ihrer herstellung.
NO178336C (no) Analogifremgangsmåte for fremstilling av en terapeutisk aktiv benzimidazolforbindelse og mellomprodukter
ES2172343T3 (es) 14,15-ciclopropano-androstanos insaturados, procedimiento para su preparacion y formulaciones farmaceuticas que contienen estos compuestos.
AR014096A1 (es) 17 alfa,8,9-deshidroestradiol y 17 beta delta 8,9 deshidroestradiol, el uso de los mismos para la manufactura de un medicamento, una composicionfarmaceutica que los comprende y un procedimiento para su preparacion.
TH8139A (th) ซับสทิทิวเทดเบนซิมิดาโซลที่ว่องไวในการรักษาและ?กรรมวิธีสำหรับเตรียมสารนั้น

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO, UMA VEZ QUE O MESMO NAO ATENDE AO DISPOSTO NOS ARTIGOS 8O E 13 DA LPI

B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT. CL: A61K 9/28; A61K 47/38; A61K 31/4439; A61P 1/04

Ipc: A61K 9/28 (2008.04)

B12B Appeal against refusal [chapter 12.2 patent gazette]